Richard E. Uihlein - 16 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GALT
Reported as of: 16 Jan 2026
Net transaction value: +$40,000
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:44:18 UTC
Prior SEC filing: 27 Jan 2025
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt, by power of attorney

Key filing fact

Richard E. Uihlein filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 21 Jan 2026.

Key facts

This page summarizes Richard E. Uihlein's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2026, 16:44.

Change

Previous filing in this sequence was filed on 27 Jan 2025.
Current net transaction value: +$40,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001694903 Primary reporting owner

Uihlein Richard E

Relationship: Director, 10%+ Owner
Address: 4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS
Signature: Jack W. Callicutt, by power of attorney
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GALT transaction

Common Stock

Award

Transaction value: $40,000
Shares: +13,158
Change %: +0.13%
Price: $3.04
Shares after: 10,332,676
Date: 16 Jan 2026
Ownership: Direct
Footnotes: F3

GALT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 27,710
Date: 16 Jan 2026
Ownership: By Ed Uihlein Family Foundation
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +60,000
Change %
Price: $0.000000
Shares after: 60,000
Date: 16 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $3.04
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Footnote F2

The options vest 100% on December 31, 2026.

Footnote F3

These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026.

Footnote F4

The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.